Mati Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-08.
Mati Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on October 8, 2025. The filing reports $9.87M sold. Its industry group is Biotechnology. It names Robert Butchofsky (Executive Officer, Director), Christopher Muller (Executive Officer, Director), Deepank Utkhede (Director) (SEC Form D, October 8, 2025).
Is this your company?
Sell to companies like Mati Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-08 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Mati Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Mati Therapeutics Inc., from the filings we hold.
Biotechnology raises by companies based in Texas, filed within 90 days of this one, largest first.
Get an email when Mati Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Mati Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Mati Therapeutics Inc. →Get the full cited report on Mati Therapeutics Inc.
What the filing shows about Mati Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Mati Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Mati Therapeutics Inc.'s address as 101 Colorado Street, Suite 2409, Austin, TX 78701.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Mati Therapeutics Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Mati Therapeutics Inc. is a registered filer with the SEC (CIK 1574251) and has filed since 2025-09-23. 3 filings are on record, the latest on 2026-07-02.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Mati Therapeutics Inc.'s Form D of 2025-10-08 names Robert Butchofsky, Christopher Muller, Deepank Utkhede and 2 more as its officers, directors or promoters.
Its new offerings report $12.05M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200, after redirecting from https://matitherapeutics.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Robert Butchofsky is named as Executive Officer and Director on the Form D that Mati Therapeutics Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Christopher Muller is named as Executive Officer and Director on the Form D that Mati Therapeutics Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Deepank Utkhede is named as Director on the Form D that Mati Therapeutics Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Joseph Tortorice III is named as Director on the Form D that Mati Therapeutics Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Cameron Nelson is named as Executive Officer on the Form D that Mati Therapeutics Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
5 people named on the filing — 3 holding an executive role and 2 as directors only.
Named as of the 2025-10-08 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Mati Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Mati Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mati Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Mati Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Mati Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (matitherapeutics.com).
Each opens in a new tab, filled in for Mati Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Austin
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/mati-therapeutics-inc-form-d-25000001